ºñ¸¸, ³ëÈ­¹æÁö
ÇǺι̿ë, ¼ºÇü
³ëÈ­¹æÁö ¿¬±¸È¸

Å»¸ð, ¾î¶² Ä¡·á¹ýÀÌ ÀÖÀ»±î?/ºÒ»õ

 
ºÒ»õ


Ãâó : http://www.youtube.com/watch?v=mUwdyN27TWI&feature=related


 
Å»¸ð, ¾î¶² Ä¡·á¹ýÀÌ ÀÖÀ»±î?
Å»¸ð°¡ ¾ðÁ¦ºÎÅÍ º´À¸·Î ÀνĵDZ⠽ÃÀÛÇß´ÂÁö´Â ¾Ë ¼ö ¾ø´Ù. ÇÏÁö¸¸, ÇǺκ´ÀÌµç ¸¶À½ÀÇ º´À̵ç Ä¡·á¹Þ°í ½Í¾î º´¿øÀ» ã°í, Ä¡·á¸¦ À§ÇØ ÀÇ»çµé ¶ÇÇÑ ¿¬±¸¿¡ ¸ÅÁøÇÏ°í ÀÖÀ¸´Ï º´À̶ó°í ºÁµµ ¹«¹æÇÒ °Í °°´Ù. ¾ÆÆÄ Á×´Â º´Àº ¾Æ´ÏÁö¸¸, ¿Ü¸ðÁö»óÁÖÀÇ¿¡¼­ »ì¾Æ³²±â À§ÇØ Å»¸ð°ü·Ã ½ÃÀåÀº ¸Å³â °©ÀýÀÇ ¼ºÀåÀ» ÇÏ°í ÀÖ´Ù. µ·ÀÌ ¸ô¸®¸é ±¤°í ¸¶ÄÉÆõµ ±â½ÂÀ» ºÎ·Á ¼ÒºñÀÚµéÀÇ ¼±ÅÃÀ» ¿ÀÈ÷·Á ´õ ¾î·Á¿öÁö±âµµ ÇÑ´Ù. Å»¸ð·Î °í¹ÎÇϴ ģ±¸¿¡°Ô ÀÇ»ç ±ô½ÅÀº ¾î¶² Ä¡·á¸¦ ±ÇÇÒ±î.


ÇöÀç Å»¸ð Ä¡·á¸¦ ¸ñÀûÀ¸·Î °³¹ßµÈ »óÇ°Àº Á·È÷ ¼ö½Ê °¡Áö ÀÌ»ó¿¡ ´ÞÇÒ °Å´Ù. ¹°·Ð, »óÇ° °³¹ß¾÷üµéÀº ÀڽŵéÀÇ ¿¬±¸ µ¥ÀÌÅ͸¦ ±âÁØÀ¸·Î ´ë¸Ó¸®À̽ŠºÐµéÀÇ °¡½¿À» ¼³·¹°Ô ÇÑ´Ù. ÇÏÁö¸¸, ±»ÀÌ ÀÇ»çÀÎ ³»°¡ ¾Æ´Ï´õ¶óµµ ±× ¾ç¹Ýµé À̾߱⸦ ¸ðµÎ ¹ÏÀ» ¼ö´Â ¾øÀ» °Å´Ù. ¾î¶² À̾߱Ⱑ ÀÇÇа迡¼­ ÇÕÀÇ(consensus)¸¦ ÀÌ·ç·Á¸é, È¿°ú°¡ ÀÖ´Ù´Â ³í¹® ÇѵΠÆíÀ¸·Î´Â ºÎÁ·ÇÏ´Ù. È¿°ú°¡ ÀÖ´Ù´Â ³í¹®µéÀÌ ¼ö½Ê Æí¿¡ ´ÞÇÏ°Ô ¹ßÇ¥°¡ µÇ°í, ±× À̾߱⸦ óÀ½ Çß´ø »ç¶÷ÀÌ ±× ºÐ¾ß ÃÖ°íÀÇ ¼®ÇÐÀ¸·Î ¸í¼ºÀ» ¾ò°Å³ª. Â÷¶ó¸® È¿°ú°¡ ¾ø´Ù´Â ºÎÁ¤ÀûÀÎ ³í¹®µé ¶ÇÇÑ ÇÔ²² ¹ßÇ¥°¡ µÇ¸ç, Áٴٸ®±â ³¡¿¡ È¿°ú°¡ ÀÖ´Â ÆíÀ¸·Î °á·Ð³ª´Â °æ¿ì°¡ ÈξÀ ¹ÏÀ»¸¸ÇÏ´Ù. ±×·¡¼­ ¿À´ÃÀº ÀÇ»çµé »çÀÌ¿¡¼­ ³ª¸§ ÇÕÀÇ°¡ ÀÌ·ç¾îÁø Ä¡·áÁ¦¿¡ ´ëÇؼ­¸¸ ¾ð±ÞÇÏ·Á ÇÑ´Ù.


1.  ¹Ì³ì½Ãµô (Minoxidil)  

°¡Àå ³Î¸® ¾Ë·ÁÁø ¹Ù¸£´Â Å»¸ðÄ¡·áÁ¦, Áï ¹ß¸ðÁ¦´Ù. µ¿ÀÏ ¼ººÐÀ» Æ÷ÇÔÇÑ ¿©·¯ Á¦Ç°ÀÌ ½ÃÆǵǰí ÀÖ°í, ¿¹Àü¿¡´Â ¹Ì³ì½Ãµô ¼ººÐ 2%ÀÇ Á¦Ç°ÀÌ ´ëºÎºÐÀ̾ú´Âµ¥, ¿äÁò¿£ 5% Á¦Ç°µéÀÌ ´Ù¼ö¸¦ ÀÌ·ç°í ÀÖ´Ù.

±â  Àü        

¹Ì³ì½ÃµôÀº ¸ð³¶ÀÇ »ý·Îº´»ç °úÁ¤ Áß ¼ºÀå ´Ü°è¸¦ ´Ã·ÁÁÜÀ¸·Î Çؼ­ ¸ð¹ß ¼ºÀåÀ» ÃËÁøÇÑ´Ù.

¹Ù¸£´Â ¹æ¹ý   

´ç±Ù ¸Ó¸®Ä«¶ôÀÌ ¾Æ´Ñ µÎÇÇ¿¡ ¹ß¶ó¾ß ÇÑ´Ù. 1cc¾¿ ÇÏ·ç¿¡ µÎ ¹ø ¹ß¸ð¸¦ ¿øÇÏ´Â ºÎÀ§¿¡ ¹Ù¸£¸é µÈ´Ù.

Ä¡·á ¿¹»ó °æ°ú

1. ÇÏ·ç¿¡ 2¹ø¾¿ ²ÙÁØÈ÷ ¹ß¶ó¾ß 4°³¿ù ÈÄ Á¤µµ¿¡ È¿°ú°¡ ³ªÅ¸³­´Ù.
2. ÃÖ´ë È¿°ú´Â 12°³¿ù¿¡¼­ 18°³¿ù Á¤µµ ²ÙÁØÈ÷ »ç¿ëÇßÀ» ¶§ µµ´ÞÇÑ´Ù°í µÇ¾î ÀÖ´Ù.
3. Ä¡·á¸¦ Áß´ÜÇϸé, Å»¸ð´Â ¹Ù·Î ´Ù½Ã ÁøÇàÇÑ´Ù. ¤Ð.¤Ð
4. Å»¸ð°¡ ½ÃÀÛµÈ Áö Àû¾îµµ 5³â À̳»¿¡ Ä¡·áÇØ¾ß ÃÖ°íÀÇ È¿°ú¸¦ º¼ ¼ö ÀÖ´Ù.
5. Á¤¼ö¸®ºÎÀ§ Å»¸ð¿¡¼­ ´õ È¿°úÀûÀÌ´Ù.
6. ³²¼º, ¿©¼ºÇü Å»¸ð¿¡ ¸ðµÎ »ç¿ë °¡´ÉÇÏ´Ù.

»ç¿ëÀÚ »ðÀÔ À̹ÌÁö

Olsen, EA, Whiting, D, Bergfeld, W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007; 57:767.



¹Ì³ì½ÃµôÀÇ È¿°ú¸¦ °ËÁõÇß´ø ´ëÇ¥ ³í¹®ÀÇ ±×·¡ÇÁ´Ù.


ºÎ ÀÛ ¿ë       

¹Ù¸£´Â ¹Ì³ì½ÃµôÀº ºÎÀÛ¿ëÀÌ °ÅÀÇ ¾ø´Â °Ô °¡Àå Å« ÀåÁ¡À̱ä ÇÏ´Ù. ÇÏÁö¸¸, °¡²û ÇǺΠÀÚ±Ø Áõ»ó Á¤µµ´Â º¸°íµÇ°í ÀÖ´Ù. ¶Ç, ½ÉÀ庴 °ú°Å·ÂÀÌ ÀÖ´Â ºÐµéÀº ÁÖÀÇ°¡ ÇÊ¿äÇÏ´Ù. °¡²û ½É¹Ú¼ö°¡ »¡¶óÁö°Å³ª ¼Õ, ¹ßÀÌ º×°í, ¸ö¹«°Ô°¡ ´À´Â ºÎÀÛ¿ëÀÌ ¹ß»ý °¡´ÉÇÏ´Ù.


2. ÇÁ·ÎÆä½Ã¾Æ (Finasteride) / ¾Æº¸´ÙÆ® (Dutasteride)


Àü¸³¼± Ä¡·áÁ¦¿´´ø Finasteride°¡ ¹ß¸ð¿¡µµ È¿°úÀûÀ̶ó´Â »ç½ÇÀÌ ¹àÇôÁö¸é¼­, Àå´Ô ¹®°í¸® Àâ µí °³¹ßµÈ ¹ß¸ðÁ¦°¡ ¹Ù·Î ÀÌ ¾àÀÌ´Ù. ÃÖ±Ù¿¡´Â ºñ½ÁÇÑ ±âÀüÀÇ ¾à¹°ÀÎ µÎŸ½ºÅ׸®µå(Dutasteride)µµ Å»¸ðÁ¦·Î Çã°¡°¡ µÇ¾ú´Ù.

±â  Àü        

°íȯ°ú ºÎ½Å¿¡¼­ ¸¸µé¾îÁö´Â Å×½ºÅ佺Å×·ÐÀ̶ó´Â È£¸£¸óÀº Ç÷·ù¸¦ Ÿ°í µ¹¾Æ´Ù´Ï´Ù°¡ ¸ð³¶ ¼¼Æ÷ ¼ÓÀ¸·Î µé¾î°¡¸é, 5-¾ËÆÄ ¸®´öŸÁ¦¶ó´Â È¿¼ÒÀÇ ¿µÇâÀ» ¹Þ¾Æ, DHT(dihydrotestosterone)ÇüÅ·Π¸ð¾çÀ» ¹Ù²ï µÚ, ¸ð³¶ÀÇ À§Ãà°ú ¸ð³¶ Æı«¸¦ À¯µµÇÑ´Ù. ÀÌ °úÁ¤¿¡¼­ ÇÁ·ÎÆä½Ã¾Æ´Â 5-¾ËÆÄ ¸®´öŸÁ¦¸¦ ¹æÇØÇÔÀ¸·Î½á Å»¸ð¸¦ Ä¡·áÇÑ´Ù.

Mechanism of action

Testosterone is produced in the testicles and the adrenal glands and carried in the bloodstream by sex hormone-binding globulin, a protein produced in the liver, which delivers it to the tissues. Inside the cells, testosterone is converted into dihydrotestosterone (DHT), which is required for its functioning because DHT has a much higher affinity to the androgen receptor, an intracellular receptor which mediates the effect of the hormones on numerous functions. The conversion of testosterone to DHT is done by two isoforms of the enzyme 5-alpha reductase.

In the prostate, inhibition of 5-alpha reductase leads to a reduction of prostate volume and hence improves the symptoms of benign prostatic hyperplasia and reduces the risk of prostate cancer. In hair follicles, DHT is needed for the initiation and progression of follicular miniaturization and eventual destruction of hair follicles in male pattern baldness.
(reference :http://en.wikipedia.org/wiki/Finasteride#Mechanism_of_action)


º¹¿ë ¿ä·É      

ÇÏ·ç¿¡ µü ÇÑ ¹ø ÇÁ·ÎÆä½Ã¾Æ ¶Ç´Â ¾Æº¸´ÙÆ®¸¦ º¹¿ëÇÑ´Ù.

Ä¡·á ¿¹»ó°æ°ú (finasteride ÀÚ·á) 

1. 12°³¿ù º¹¿ë±îÁö ²ÙÁØÈ÷ ¹ß¸ð È¿°ú°¡ Áõ´ëµÈ´Ù°í º¸°íµÈ´Ù.
2. ÃÖ°í È¿°ú´Â 12°³¿ù¿¡¼­ 24°³¿ù »çÀÌ Á¤µµ¿¡ ³ªÅ¸³­´Ù.
3. ¹°·Ð, º¹¿ëÀ» Áß´ÜÇϸé Å»¸ð´Â ´Ù½Ã ÁøÇàµÈ´Ù.
4. ¿©¼ºÇü Å»¸ð¿¡´Â »ç¿ëµÇÁö ¾Ê´Â´Ù.

»ç¿ëÀÚ »ðÀÔ À̹ÌÁö

Kaufman, KD, Olsen, EA, Whiting, D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998; 39:578.


ºÎ ÀÛ ¿ë    

Àü¸³¼± ºñ´ëÁõ¿¡¼­ »ç¿ëµÇ´Â ÇÏ·ç 5mgÀÇ °æ¿ì¿¡´Â ¹ß±âºÎÀüÀ̳ª ¼º¿å °¨Åð µîÀÇ ¼º ±â´É¿¡ °ü·ÃµÈ ºÎÀÛ¿ëÀÌ ¶§·Î º¸°íµÇÁö¸¸, Å»¸ð Ä¡·á¸¦ À§ÇÑ ÇÏ·ç 1mg ¿ë¹ý¿¡¼­´Â ¾ÆÁÖ ÀûÀº °æ¿ì¿¡¼­¸¸ ³ªÅ¸³­´Ù.

³²¾Æ¸¦ ÀÓ½ÅÇÑ ¿©¼ºµéÀÌ ÀÌ ¾à¿¡ ³ëÃâµÈ °æ¿ì º¹Áß Å¾ÆÀÇ ¼º ¹ß´Þ¿¡ Àå¾Ö°¡ ¹ß»ýÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇ°¡ ÇÊ¿äÇÏ´Ù.


3. ½ºÇǷγë¶ôÅæ (Spironolactone)  

ÀÌ´¢Á¦ÀÇ ÀÏÁ¾À¸·Î ¾Ëµµ½ºÅ×·ÐÀ̶ó´Â È£¸£¸óÀÇ ÀÛ¿ëÀ» ¾ïÁ¦ÇÑ´Ù.
³Î¸® »ç¿ëµÇ°í ÀÖ´Â Å»¸ð Ä¡·áÁ¦´Â ¾Æ´ÏÁö¸¸, ¹Ì³ì½Ãµô¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â ¿©¼ºÇü Å»¸ð¿¡¼­ ÀÌ¿ëµÇ°í ÀÖ´Ù.


4. ¼ö¼úÀû Ä¡·á : ¸ð¹ß ÀÌ½Ä      


¿©·¯ ¼ú½ÄÀÌ ¼Ò°³µÇ¸é¼­ À̽ÄÇÑ ¸ð¹ßÀÇ »ýÂø·üÀÌ Áö¼ÓÀûÀ¸·Î ¿À¸£°í ÀÖ´Ù. ¿ø¸®´Â °£´ÜÇÏ´Ù. Å»¸ð ÁøÇàÀÌ ´õµò ÁÖº¯¸Ó¸®¿Í µÞ¸Ó¸®¸¦ Å»¸ðµÈ ºÎÀ§¿¡ ¿Å°Ü ½É´Â ¹æ¹ýÀÌ´Ù. °¡Àå È®½ÇÇÑ ¹æ¹ýÀ̱ä ÇÏÁö¸¸, º´ÇàµÇ´Â Åõ¾àÄ¡·á°¡ ¾ø´Ù¸é, Àå±âÀûÀÎ ¼º°ø¿¡ Á¦ÇÑÀÌ ÀÖ´Ù. ¿Ö³Ä¸é Å»¸ð´Â ½Ã°£ÀÌ Áö³ª¸é¼­ °è¼Ó ÁøÇàµÇ±â ¶§¹®ÀÌ´Ù.


¾²´Ù º¸´Ï, ¿À´Ã Æ÷½ºÆÃÀº Á¦¾àȸ»ç³ª Å»¸ðŬ¸®´Ð ±¤°í °°Àº ´À³¦ÀÌ µé±âµµ ÇÑ´Ù. ÇÏÁö¸¸, »ç½Ç ³»°¡ ¿À´Ã ÇÏ°í ½Í¾ú´ø ÁøÂ¥ À̾߱â´Â À§ ¼ººÐÀÇ ¾àµéÀÌ ¾Æ´Ï¶ó, ±× ¿ÜÀÇ Ä¡·á´Â È¿°ú¸¦ Àå´ãÇÒ ¼ö ¾ø´Ù´Â ¾ê±â¿´´ÂÁöµµ ¸ð¸¥´Ù. Àû¾îµµ Å»¸ð·Î °í¹ÎÇÏ´Â ±ô½ÅÀÇ Ä£±¸¶ó¸é, ¹Ì³ì½Ãµô ¹Ù¸£¸é¼­ ÇÁ·ÎÆä½Ã¾Æ¸¦ ¸Ô¾îº¸°í, 1³â Á¤µµ ±â´Ù¸®°í¼­µµ °á°ú°¡ ¸¸Á·½º·´Áö ¾Ê´Ù¸é, ¸ð¹ßÀÌ½Ä µîÀ» ±ÇÇÏ°í ½Í´Ù. È¿°ú°¡ ¾ÆÁ÷ °ËÁõµÇÁöµµ ¾ÊÀº Ä¡·á¹ý¿¡ ¾Æ±î¿î µ·À» ³¶ºñÇÏ´Â °Í. ÀÌ°Ô ¹Ù·Î ±ô½ÅÀÌ °¡Àå ¾ÈŸ±î¿öÇÏ´Â ÀÏÀÌ´Ù.


Âü°í ¹®Çå :

Olsen, EA. Androgenetic alopecia. In: Disorders of hair growth: Diagnosis and treatment, Olsen, EA (Ed), McGraw-Hill, New York 1994. p.257.
Olsen, EA, Whiting, D, Bergfeld, W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007; 57:767.
Price, VH, Menefee, E, Strauss, PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999; 41:717.
Kaufman, KD, Olsen, EA, Whiting, D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998; 39:578.
http://www.aad.org/public/publications/pamphlets/common_hairloss.html
http://en.wikipedia.org/wiki/Finasteride#Mechanism_of_action  


by ÇÑ°øâ  at  2010.06.16. 12:22

[ÀÌÀü±Û] : ³ëÈ­¹æÁö´º½º/Ã౸Àå¿¡¼­ ¹è¿ï Á¡/Ã౸ Äڹ̵ð
[´ÙÀ½±Û] : Áٱ⼼Æ÷ ¿¬±¸.µ¿Ç⺸°í¼­-¿ªºÐÈ­ ¸¸´É ¼¼Æ÷À» Áß½ÉÀ¸·Î


°Ô½Ã¹° ¸ñ·ÏÀ» º¾´Ï´Ù.